



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 211/22, 211/32, 401/12, A61K 31/445		A1	(11) International Publication Number: WO 95/04042			
			(43) International Publication Date: 9 February 1995 (09.02.95)			
(21) International Application Number:	PCT/GB94/01576		(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).			
(22) International Filing Date:	21 July 1994 (21.07.94)					
(30) Priority Data:	9315808.7	30 July 1993 (30.07.93)	GB			
(71) Applicant (for all designated States except US):	MERCK SHARP & DOHME LIMITED [GB/GB]; Hertford Road, Hoddesdon, Hertfordshire EN11 9BU (GB).					
(72) Inventors; and						
(75) Inventors/Applicants (for US only):	MACLEOD, Angus, Murray [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). MERCHANT, Kevin, John [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). STEVENSON, Graeme, Irvine [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB).					
(74) Agent:	HISCOCK, Ian, James; Merck & Co., Inc., Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB).					
Published						
<i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>						

(54) Title: 4-PHENYL-4-PHENYLPROPYL(ENYL)-PIPERIDINES AS TACHYKININ ANTAGONISTS

(57) Abstract

The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts and prodrugs thereof, wherein X represents a propylene or propenylene chain optionally substituted by one or more of R⁴, R⁵, R⁶ and R⁷; m is 2, 3 or 4; n is 0, 1 or 2 when m is 2 or 3, and n is 0 or 1 when m is 4; R¹ represents optionally substituted phenyl; R² represents optionally substituted phenyl, heteroaryl, benzhydryl or benzyl; R³ represents H, COR⁹, CO₂R¹⁰, COCONR¹⁰R¹¹, COCO₂R¹⁰, SO₂R¹⁵, CONR¹⁰SO₂R¹⁵, C₁-alkyl optionally substituted by a group selected from (CO₂R¹⁰, CONR¹⁰R¹¹, hydroxy, cyano, COR⁹, NR¹⁰R¹¹, C(NO₂)NR¹⁰R¹¹, CONHphenyl(C₁-alkyl), COCO₂R¹⁰, COCONR¹⁰R¹¹, SO₂R¹⁵, CONR¹⁰SO₂R¹⁵ and optionally substituted phenyl), Y-R⁸ or CO-Z-(CH₂)_q-R¹², R⁴ and R⁵ each independently represent H, C₁-alkyl, C₃-cycloalkyl, C₃-cycloalkylmethyl, hydroxy or C₁-alkoxy, or R⁴ and R⁵ together form a group =O; R⁶ and R⁷ each independently represent H, C₁-alkyl, C₃-cycloalkyl, C₃-cycloalkylmethyl, hydroxy or C₁-alkoxy or R⁶ and R⁷ together form a group =O; R⁸ represents an optionally substituted aromatic heterocycle; R⁹ represents H, C₁-alkyl, C₃-cycloalkyl, C₃-cycloalkylmethyl, or phenyl; R¹⁰ and R¹¹ each independently represent H, C₁-alkyl, C₃-cycloalkyl or C₃-cycloalkylmethyl; R¹² represents NR¹²R¹⁴ or an optionally substituted aromatic or non-aromatic azacyclic or azabicyclic group; R¹³ and R¹⁴ each independently represent H, C₁-alkyl, C₃-cycloalkyl, C₃-cycloalkylmethyl, optionally substituted phenyl or phenylC₁-alkyl; R¹⁵ represents C₁-alkyl, C₃-cycloalkyl, C₃-cycloalkylmethyl, trifluoromethyl or optionally substituted phenyl; Y represents a hydrocarbon chain of 1, 2, 3 or 4 carbon atoms which may optionally be substituted by oxo; Z represents CH₂, O, S or NR¹⁶, and q represents 0, 1, 2, 3, 4, 5 or 6. The compounds are tachykinin antagonists useful for treating pain or inflammation, migraine or emesis.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroun	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

4-PHENYL-4-PHENYLPROPYL(ENYL)-PIPERIDINES AS TACHYKININ ANTAGONISTS.

5 This invention relates to a class of azacyclic compounds, which are useful as tachykinin antagonists. More particularly, the compounds of the invention comprise an azacyclic ring system substituted by an aryl moiety and an arylalkyl or arylalkenyl moiety.

10 The tachykinins are a group of naturally-occurring peptides found widely distributed throughout mammalian tissues, both within the central nervous system and in the peripheral nervous and circulatory systems.

The tachykinins are distinguished by a conserved carboxy-terminal sequence:

15 Phe-X-Gly-Leu-Met-NH₂

At present, there are three known mammalian tachykinins referred to as substance P, neurokinin A (NKA, substance K, neuromedin L) and neurokinin B (NKB, neuromedin K) (for review see J.E. Maggio, Peptides 20 (1985) 6 (suppl. 3), 237-242). The current nomenclature designates the three tachykinin receptors mediating the biological actions of substance P, NKA and NKB as the NK₁, NK₂ and NK₃ receptors, respectively.

25 Evidence for the usefulness of tachykinin receptor antagonists in pain, headache, especially migraine, Alzheimer's disease, multiple sclerosis, attenuation of morphine withdrawal, cardiovascular changes, oedema, such as oedema caused by thermal injury, chronic inflammatory diseases such as rheumatoid 30 arthritis, asthma/bronchial hyperreactivity and other respiratory diseases including allergic rhinitis, inflammatory diseases of the gut including ulcerative colitis and Crohn disease, ocular injury and ocular inflammatory diseases, proliferative vitreoretinopathy,

- 2 -

irritable bowel syndrome and disorders of bladder function including cystitis and bladder detruser hyper-reflexia is reviewed in "Tachykinin Receptors and Tachykinin Receptor Antagonists", C.A. Maggi, R. 5 Patacchini, P. Rovero and A. Giachetti, J. Auton. Pharmacol. (1993) 13, 23-93. Tachykinin antagonists may also be useful in the treatment of emesis [F.D. Tattersall et. al., Eur. Pharmacol., (1993) 250, R5-R6]. Tachykinin antagonists are also believed to be useful in 10 allergic conditions [Hamelet et al Can. J. Pharmacol. Physiol. (1988) 66 1361-7], immunoregulation [Lotz et al Science (1988) 241 1218-21 and Kimball et al, J. Immunol. (1988) 141 (10) 3564-9], and as anticonvulsants [Garant et al., Brain Research (1986) 382 372-8]. Tachykinin 15 antagonists may also be useful in the treatment of small cell carcinomas, in particular small cell lung cancer (SCLC) [Langdon et al., Cancer Research (1992) 52, 4554-7].

It has furthermore been suggested that 20 tachykinins have utility in the following disorders: depression, dysthymic disorders, chronic obstructive airways disease, hypersensitivity disorders such as poison ivy, vasospastic diseases such as angina and Reynaud's disease, fibrosing and collagen diseases such 25 as scleroderma and eosinophilic fascioliasis, reflex sympathetic dystrophy such as shoulder/hand syndrome, addiction disorders such as alcoholism, stress related somatic disorders, neuropathy, neuralgia, disorders related to immune enhancement or suppression such as 30 systemic lupus erythematosus (European patent specification no. 0 436 334), conjunctivitis, vernal conjunctivitis, contact dermatitis, atopic dermatitis, urticaria, and other eczematoid dermatitis (European patent specification no. 0 394 989).


- 3 -

In view of their metabolic instability, peptide derivatives are likely to be of limited utility as therapeutic agents. It is for this reason that non-peptide tachykinin antagonists are sought.

5 In essence, this invention provides a class of potent non-peptide tachykinin antagonists.

The present invention provides a compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof:

10



wherein

20 X represents a propylene or propenylene chain optionally substituted by one or more of R⁴, R⁵, R⁶ and R⁷;

m is 2, 3 or 4;

25 n is 0, 1 or 2 when m is 2 or 3, and n is 0 or 1 when m is 4;

30 R¹ represents phenyl optionally substituted by 1, 2 or 3 groups selected from C₁-6alkyl, C₂-6alkenyl, C₂-6alkynyl, C₃-6cycloalkyl, C₃-5cycloalkylmethyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, -OR^a, -SR^a, -SOR^a, -SO₂R^a, -NR^aR^b, -NR^aCOR^b, -NR^aCO₂R^b, -CO₂R^a or -CONR^aR^b, where R^a and R^b each independently represent H, C₁-6alkyl, phenyl or trifluoromethyl;

R² represents phenyl optionally substituted by 1, 2 or 3 groups selected from C₁-6alkyl, C₂-6alkenyl,

- 4 -

C_2 -6alkynyl, C_3 -6cycloalkyl, C_3 -5cycloalkylmethyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, -OR^a, -SR^a, -SOR^a, -SO₂R^a, -NR^aR^b, -NR^aCOR^b, -NR^aCO₂R^b, -CO₂R^a or -CONR^aR^b, where R^a and R^b are as previously defined;

5 heteroaryl selected from indazolyl, thienyl, furyl, pyridyl, thiazolyl, tetrazolyl and quinolyl; benzhydryl; or benzyl; wherein each heteroaryl and each phenyl moiety of benzyl and benzhydryl may be substituted by C_1 -6alkyl, C_1 -6alkoxy, halo or trifluoromethyl;

10 R³ represents H, COR⁹, CO₂R¹⁰, COCONR¹⁰R¹¹, COCO₂R¹⁰, SO₂R¹⁵, CONR¹⁰SO₂R¹⁵, C_1 -6alkyl optionally substituted by a group selected from (CO₂R¹⁰, CONR¹⁰R¹¹, hydroxy, cyano, COR⁹, NR¹⁰R¹¹, C(NOH)NR¹⁰R¹¹, CONHphenyl(C_1 -4alkyl), COCO₂R¹⁰, COCONR¹⁰R¹¹, SO₂R¹⁵,

15 CONR¹⁰SO₂R¹⁵ and phenyl optionally substituted by one or more substituents selected from C_1 -6alkyl, C_1 -6alkoxy, halo and trifluoromethyl), Y-R⁸ or CO-Z-(CH₂)_q-R¹²;

R⁴ and R⁵ each independently represents H, C_1 -6alkyl, C_3 -6cycloalkyl, C_3 -5cycloalkylmethyl, hydroxy

20 or C_1 -6alkoxy, or R⁴ and R⁵ together form a group =O;

R⁶ and R⁷ each independently represents H, C_1 -6alkyl, C_3 -6cycloalkyl, C_3 -5cycloalkylmethyl, hydroxy or C_1 -6alkoxy or R⁶ and R⁷ together form a group =O;

25 R⁸ represents an optionally substituted aromatic heterocycle;

R⁹ represents H, C_1 -6alkyl, C_3 -6cycloalkyl, C_3 -5cycloalkylmethyl, or phenyl;

R¹⁰ and R¹¹ each independently represent H, C_1 -6alkyl, C_3 -6cycloalkyl or C_3 -5cycloalkylmethyl;

30 R¹² represents NR¹³R¹⁴ or an optionally substituted aromatic or non-aromatic azacyclic or azabicyclic group;

- 5 -

R¹³ and R¹⁴ each independently represent H, C₁-6alkyl, C₃-6cycloalkyl, C₃-5cycloalkylmethyl, phenyl optionally substituted by one or more of C₁-6alkyl, C₁-6alkoxy, halo or trifluoromethyl or phenylC₁-4alkyl
5 optionally substituted in the phenyl ring by one or more of C₁-6alkyl, C₁-6alkoxy, halo or trifluoromethyl; R¹⁵ represents C₁-6alkyl, C₃-6cycloalkyl, C₃-5cycloalkylmethyl, trifluoromethyl or phenyl optionally substituted by one or more substituents
10 selected from C₁-6alkyl, C₁-6alkoxy, halo and trifluoromethyl;
Y represents a hydrocarbon chain of 1, 2, 3 or 4 carbon atoms which may optionally be substituted by oxo;
15 Z represents CH₂, O, S or NR¹⁰; and q represents 0, 1, 2, 3, 4, 5 or 6.
As used herein, the definition of each expression, when it occurs more than once in any structure, is intended to be independent of its definition elsewhere in the same structure.

20 The alkyl, alkenyl and alkynyl groups referred to with respect to the formulae herein may represent straight or branched groups. Thus, for example, suitable alkyl groups include methyl, ethyl, n- or iso-propyl and n-, sec-, iso- or tert-butyl. The cycloalkyl groups referred to above may be, for example, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. Similarly, suitable cycloalkylmethyl groups include cyclopropylmethyl; suitable alkenyl groups include vinyl and allyl; and suitable alkynyl groups include propargyl.
25
30

The term "halo" as used herein includes fluoro, chloro, bromo and iodo, especially chloro and fluoro.

The present invention includes within its scope prodrugs of the compounds of formula (I) above. In

- 6 -

general, such prodrugs will be functional derivatives of the compounds of formula (I) which are readily convertible in vivo into the required compound of formula (I). Conventional procedures for the selection and 5 preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.

Those compounds according to the invention which contain one or more chiral centres may exist both 10 as enantiomers and as diastereomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention.

Preferably m is 2.

When m is 2, n is preferably 2. When m is 3 or 15 4, n is preferably 0.


A preferred class of compounds of formula (I) is that wherein X represents a group $CR^4R^5CH_2CR^6R^7$, $CR^4=CHCR^6R^7$ or $CR^4R^5CH=CR^6$.

Suitably R^4 and R^5 each independently 20 represents H, methyl, hydroxy or methoxy or R^4 and R^5 together represent =0.

Suitably R^6 and R^7 each independently represents H, methyl, hydroxy or methoxy or R^6 and R^7 together represent =0.

25 Suitable values for the group X include:

- 7 -



Preferably X represents $CR^4R^5CH_2CR^6R^7$ such as $CH_2CH_2CH_2$, $CH(OH)CH_2CH_2$ or $CH_2CH_2CH(OH)$. Preferably X represents $CH_2CH_2CH(OH)$.

Preferably R^1 represents substituted phenyl.

15 When R^1 is substituted phenyl suitable substituents include nitro, trifluoromethyl, trimethylsilyl, bromo, chloro, fluoro, iodo, cyano, methyl, ethyl, cyclopropyl, t-butyl, vinyl, methoxy, phenoxy, amino and carbonylmethoxy. Preferably R^1 represents phenyl substituted by one or more groups selected from C_1 - C_6 alkyl such as methyl and t-butyl, halo such as chloro, fluoro and bromo, and trifluoromethyl.

20
25 Preferably R^1 represents disubstituted phenyl, in particular 3,5-disubstituted phenyl, for example 3,5-disubstituted phenyl wherein the substituents are selected from C_1 - C_6 alkyl, halo and trifluoromethyl. More preferably R^1 represents 3,5-bis(trifluoromethyl)phenyl.

30 Suitable values for the group R^2 include unsubstituted or substituted phenyl, 5-membered heteroaryl such as thienyl, 6-membered heteroaryl such as pyridyl, and benzhydryl.

Preferably R^2 represents unsubstituted or substituted phenyl.

- 8 -

When R^2 represents substituted phenyl a preferred substituent is halo, especially fluoro.

When R^8 represents a substituted aromatic heterocycle, suitable substituents in the heterocyclic ring include one or more of C_1 - 6 alkyl, C_3 - 6 cycloalkyl, C_3 - 5 cycloalkylmethyl, C_1 - 6 alkoxy, phenyl, oxo, thioxo, halo, trifluoromethyl, NR^aR^b , NR^aCOR^b , $CONR^aR^b$, CO_2R^a , SR^a , SO_2R^a and CH_2OR^a , where R^a and R^b are as previously defined. Particular examples of suitable substituents include methyl, methoxy, phenyl, oxo, thioxo, bromo, iodo, NH_2 , SCH_3 , $CONH_2$ and cyano. Particularly preferred substituents include oxo and NH_2 .

Suitable values for R^8 include thienyl, furyl, pyrrolyl, pyridyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, oxazolyl, oxadiazolyl, thiadiazolyl, isoxazolyl, quinolyl, isothiazolyl, imidazolyl, benzimidazolyl, benzoxazolyl, benzothiophenyl, benzofuranyl and indolyl, any of which may be substituted.

Preferably R^8 represents a substituted or unsubstituted 5- or 6-membered nitrogen containing aromatic heterocycle such as for example oxazolyl, oxadiazolyl, tetrazolyl, thiazolyl, thiadiazolyl, triazolyl, pyrazinyl, pyridyl, pyrimidinyl, pyridazinyl, imidazolyl or triazinyl. More preferably R^8 represents optionally substituted oxazolyl, oxadiazolyl, imidazolyl, thiadiazolyl, triazolyl, pyrazinyl, pyrimidinyl, pyridazinyl or triazinyl, or tetrazolyl substituted by C_1 - 6 alkyl, preferably methyl.

It will be appreciated that, when the heterocyclic moiety R^8 is substituted by an oxo or thioxo substituent, different tautomeric forms are possible so that the substituent may be represented as $=O$ or $-OH$, or

- 9 -

=S or -SH, respectively. For the avoidance of doubt, all such tautomeric forms are embraced by the present invention.

When R^{12} represents $NR^{13}R^{14}$, R^{13} and R^{14} are 5 preferably both C_{1-6} alkyl such as methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl or t-butyl. More preferably R^{13} and R^{14} will both represent methyl.

When R^{12} represents an aromatic or non-aromatic azacycle or azabicycle it may contain one or more 10 additional heteroatoms selected from O, S and N or groups NR^{16} , where R^{16} is H, C_{1-6} alkyl or phenyl C_{1-4} alkyl, and may be unsubstituted or substituted. Suitable 15 substituents include C_{1-6} alkyl, C_{1-6} alkoxy, oxo, SH, =S, halo, trifluoromethyl, NR^aR^b , NR^aCOR^b , $CONR^aR^b$, CO_2R^a and CH_2OR^a , where R^a and R^b are as previously defined.

When R^{12} represents an aromatic azacycle or azabicycle, suitable values of R^{12} include imidazolyl, triazolyl, tetrazolyl, oxazolyl, thiazolyl, pyrrolyl, pyrazolyl, pyrazinyl, pyridyl, oxadiazolyl, thiadiazolyl, 20 isoxazolyl, isothiazolyl, benzimidazolyl, benzoxazolyl and indolyl, preferably imidazolyl, such as 2,4-imidazolyl, or pyridyl, more preferably pyridyl such as 4-, 3- or 2-pyridyl.

When R^{12} represents a non-aromatic azacycle or azabicycle, suitable values of R^{12} include morpholinyl, piperdinyl, pyrrolidinyl, piperazinyl, methylpiperazinyl, azanorbornanyl, azabicyclo[2.2.2]octanyl and azabicyclo[3.2.2]nonyl, preferably morpholinyl, methylpiperazinyl, quinuclidinyl (azabicyclo[2.2.2]octanyl) or azabicyclo[3.2.2]nonyl, more preferably quinuclidinyl.

Suitably Y represents a hydrocarbon chain of 1 or 2 carbon atoms optionally substituted by oxo, such as CH_2 , $C=O$, $CH(CH_3)$, $CH_2(C=O)$ or $(C=O)CH_2$. Preferably Y

- 10 -

represents CH_2 , $\text{CH}(\text{CH}_3)$ or $\text{CH}_2(\text{C=O})$, more preferably CH_2 or $\text{CH}(\text{CH}_3)$.

Suitably q represents 0, 1, 2 or 3.

Suitable values of R^3 include H, COR^9 such as

5 COCH_3 , SO_2R^{15} such as SO_2CH_3 , $\text{C}_1\text{-6alkyl}$ such as CH_3 , $\text{CH}(\text{CH}_3)_2$, $\text{CH}_2\text{CH}(\text{CH}_3)_2$ and $\text{CH}_2\text{CH}_2\text{C}(\text{CH}_3)_3$, $\text{C}_1\text{-6alkyl}$ substituted by CO_2R^{10} such as $\text{CH}_2\text{CO}_2\text{CH}_3$, $\text{CH}_2\text{CO}_2\text{H}$, $(\text{CH}_2)_3\text{CO}_2\text{CH}_3$ and $(\text{CH}_2)_3\text{CO}_2\text{H}$, $\text{C}_1\text{-6alkyl}$ substituted by $\text{CONR}^{10}\text{SO}_2\text{R}^{15}$ such as $\text{CH}_2\text{CONHSO}_2\text{CH}_3$ and $\text{CH}_2\text{CONHSO}_2\text{C}_6\text{H}_5$,


10 $\text{C}_1\text{-6alkyl}$ substituted by phenyl, Y-R^8 and $\text{CO-Z-(CH}_2)_q\text{-R}^{12}$.

In one preferred subgroup of compounds according to the invention, R^3 represents H or $\text{C}_1\text{-6alkyl}$, more preferably H.

15 In a further preferred subgroup of compounds according to the invention R^3 represents Y-R^8 .

A yet further preferred subgroup of compounds according to the invention is represented by compounds wherein R^3 is $\text{CO-Z-(CH}_2)_q\text{-R}^{12}$.

20 A particular sub-class of compounds according to the invention is represented by compounds of formula (Ia), and pharmaceutically acceptable salts and prodrugs thereof:



(Ia)

wherein

R^3 and X are as defined for formula (I);

- 11 -

R^{20} and R^{21} independently represent H, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl, C₃₋₅cycloalkylmethyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR^a, SR^a, SOR^a, SO₂R^a, NR^aR^b, NR^aCOR^b, NR^aCO₂R^b, CO₂R^a or CONR^aR^b, where R^a and R^b are as previously defined; and
5 R^{22} represents H or halo, preferably H or fluoro.

Particular values of R^{20} and R^{21} include H, 10 chloro, bromo, methyl, t-butyl and trifluoromethyl. Preferably R^{20} and R^{21} are both other than H and are located at the 3- and 5-positions of the phenyl ring.

Specific compounds within the scope of the present invention include:

15 4-(3-(3',5'-bis(trifluoromethyl)phenyl)propionyl)-4-phenylpiperidine;
4-(3-(3',5'-bis(trifluoromethyl)phenyl)-1-hydroxy-3-propenyl)-4-phenylpiperidine;
20 4-(3-(3',5'-bis(trifluoromethyl)phenyl)-1-methoxy-3-propenyl)-4-phenylpiperidine;
4-(3-(3',5'-bis(trifluoromethyl)phenyl)-1-methoxypropyl)-4-phenylpiperidine;
25 4-(3-(3',5'-bis(trifluoromethyl)phenyl)-1-hydroxypropyl)-4-phenylpiperidine;
4-(3-(3',5'-bis(trifluoromethyl)phenyl)-3-ketopropyl)-4-phenylpiperidine;
4-(3-(3',5'-bis(trifluoromethyl)phenyl)-3-hydroxypropyl)-4-phenylpiperidine;
30 4-(3-(3',5'-bis(trifluoromethyl)phenyl)-3-methoxypropyl)-4-phenylpiperidine;
(R)-4-(3-(3',5'-bis(trifluoromethyl)phenyl)-3-hydroxypropyl)-4-phenylpiperidine;
(S)-4-(3-(3',5'-bis(trifluoromethyl)phenyl)-3-hydroxypropyl)-4-phenylpiperidine;

- 12 -

4-(3-(3',5'-bis(trifluoromethyl)phenyl)-3-hydroxy-3-methylpropyl)-4-phenylpiperidine;

4-(3-(3',5'-bis(trifluoromethyl)phenyl)-3-hydroxy-3-ethylpropyl)-4-phenylpiperidine;

5 4-(3-(3',5'-bis(trifluoromethyl)phenyl)propyl)-4-phenylpiperidine;

5-[4-(3-(3',5'-bis(trifluoromethyl)phenyl)propyl)-4-phenylpiperidin-1-ylmethyl]-2,4-dihydro-1,2,4-triazol-3-one;

10 5-[4-(3-(3',5'-bis(trifluoromethyl)phenyl)-3-hydroxypropyl)-4-phenylpiperidin-1-ylmethyl]-2,4-dihydro-1,2,4-triazol-3-one;

and pharmaceutically acceptable salts and prodrugs thereof.

15 For use in medicine, the salts of the compounds of formula (I) will be pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds according to the invention (such as the dibenzoyltartrate salts) or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable non-toxic acid such as hydrochloric acid, sulphuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid or p-toluenesulphonic acid. Salts of amine groups may also comprise quaternary ammonium salts.

20 25 30 in which the amino nitrogen atom carries a suitable organic group such as an alkyl, alkenyl, alkynyl or aralkyl moiety. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include

- 13 -

metal salts such as alkali metal salts, e.g. sodium or potassium salts; and alkaline earth metal salts, e.g. calcium or magnesium salts.

Preferred salts of the compounds according to 5 the invention include the hydrochloride and p-toluenesulphonic acid salts.

The invention also provides pharmaceutical 10 compositions comprising one or more compounds of this invention in association with a pharmaceutically acceptable carrier. Preferably these compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, solutions or suspensions, or suppositories, for oral, parenteral or rectal administration, or topical administration including 15 administration by inhalation or insufflation.

The invention further provides a process for 20 the preparation of a pharmaceutical composition comprising a compound of formula (I), or a salt or prodrug thereof, and a pharmaceutically acceptable carrier, which process comprises bringing a compound of formula (I), or a salt or prodrug thereof into association with a pharmaceutically acceptable carrier.

For preparing solid compositions such as 25 tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tabletting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid 30 preformulation composition containing a homogeneous mixture of a compound of the present invention, or a non-toxic pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is

- 14 -

dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then 5 subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the 10 advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in 15 the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such 20 materials as shellac, cetyl alcohol and cellulose acetate.

The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous 25 solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for 30 aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.

- 15 -

Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions 5 may contain suitable pharmaceutically acceptable excipients as set out above. Preferably the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in preferably sterile pharmaceutically acceptable solvents may be 10 nebulised by use of inert gases. Nebulised solutions may be breathed directly from the nebulising device or the nebulising device may be attached to a face mask, tent or intermittent positive pressure breathing machine. Solution, suspension or powder compositions may be 15 administered, preferably orally or nasally, from devices which deliver the formulation in an appropriate manner.

For topical administration, for example as a cream, ointment or lotion, pharmaceutically acceptable carriers are, for example, water, mixtures of water and 20 water-miscible solvents such as lower alkanols or arylalkanols, vegetable oils, polyalkylene glycols, petroleum based jelly, ethyl cellulose, ethyl oleate, carboxymethylcellulose, polyvinylpyrrolidone, isopropyl myristate and other conventionally-employed non-toxic, 25 pharmaceutically acceptable organic and inorganic carriers. The pharmaceutical preparation may also contain non-toxic auxiliary substances such as emulsifying, preserving, wetting agents, bodying agents and the like, as for example, polyethylene glycols 200, 300, 400 and 600, carbowaxes 1,000, 1,500, 4,000, 6,000 and 10,000, antibacterial components such as quaternary ammonium compounds, phenylmercuric salts known to have cold sterilizing properties and which are non-injurious in use, thimerosal, methyl and propyl paraben, benzyl

- 16 -

alcohol, phenyl ethanol, buffering ingredients such as sodium chloride, sodium borate, sodium acetates, gluconate buffers, and other conventional ingredients such as sorbitan monolaurate, triethanolamine, oleate, 5 polyoxyethylene sorbitan monopalmitate, dioctyl sodium sulfosuccinate, monothioglycerol, thiosorbitol, ethylenediamine tetraacetic acid, and the like.

The compounds of formula (I) are of value in the treatment of a wide variety of clinical conditions 10 which are characterised by the presence of an excess of tachykinin, in particular substance P, activity. These may include disorders of the central nervous system such as anxiety, depression, psychosis and schizophrenia; epilepsy; neurodegenerative disorders such as dementia, 15 including senile dementia of the Alzheimer type, Alzheimer's disease and Down's syndrome; demyelinating diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease) and other neuropathological disorders such as peripheral 20 neuropathy, for example, diabetic or chemotherapy-induced neuropathy, and postherpetic and other neuralgias; small cell carcinomas such as small cell lung cancer; respiratory diseases such as chronic obstructive airways disease, bronchopneumonia, bronchospasm and asthma; 25 inflammatory diseases such as inflammatory bowel disease, psoriasis, fibrositis, osteoarthritis and rheumatoid arthritis; allergies such as eczema and rhinitis; hypersensitivity disorders such as poison ivy; ophthalmic diseases such as conjunctivitis, vernal conjunctivitis, 30 and the like; cutaneous diseases such as contact dermatitis, atopic dermatitis, urticaria, and other eczematoid dermatitis; addiction disorders such as alcoholism; stress related somatic disorders; reflex sympathetic dystrophy such as shoulder/hand syndrome;

- 17 -

dysthymic disorders; adverse immunological reactions such as rejection of transplanted tissues and disorders related to immune enhancement or suppression such as systemic lupus erythematosus; gastrointestinal (GI) 5 disorders and diseases of the GI tract such as disorders associated with the neuronal control of viscera such as ulcerative colitis, Crohn's disease and incontinence; emesis, including acute, delayed and anticipatory emesis, for example, induced by chemotherapy, radiation, toxins, 10 pregnancy, vestibular disorders, surgery, migraine and variations in intracranial pressure; disorders of bladder function such as bladder detrusor hyper-reflexia; fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis; disorders of blood flow caused 15 by vasodilation and vasospastic diseases such as angina, migraine and Reynaud's disease; and pain or nociception, for example, that attributable to or associated with any of the foregoing conditions, especially the transmission of pain in migraine.

20 The compounds of formula (I) are also of value in the treatment of a combination of the above conditions, in particular in the treatment of combined post-operative pain and post-operative nausea and vomiting.

25 The compounds of formula (I) are particularly useful in the treatment of pain or nociception and/or inflammation and disorders associated therewith such as, for example, neuropathy, such as diabetic and chemotherapy-induced neuropathy, postherpetic and other 30 neuralgias, asthma, osteoarthritis, rheumatoid arthritis and especially migraine.

The present invention further provides a compound of formula (I) for use in therapy.

- 18 -

According to a further or alternative aspect, the present invention provides a compound of formula (I) for use in the manufacture of a medicament for the treatment of physiological disorders associated with an excess of tachykinins, especially substance P.

5 The present invention also provides a method for the treatment or prevention of physiological disorders associated with an excess of tachykinins, especially substance P, which method comprises 10 administration to a patient in need thereof of a tachykinin reducing amount of a compound of formula (I) or a composition comprising a compound of formula (I).

15 For the treatment of certain conditions it may be desirable to employ a compound according to the present invention in conjunction with another pharmacologically active agent. For example, for the treatment of respiratory diseases such as asthma, a compound of formula (I) may be used in conjunction with a bronchodilator, such as a β_2 -adrenergic receptor 20 antagonist or tachykinin antagonist which acts at NK-2 receptors. The compound of formula (I) and the bronchodilator may be administered to a patient simultaneously, sequentially or in combination.

25 The present invention accordingly provides a method for the treatment of a respiratory disease, such as asthma, which method comprises administration to a patient in need thereof of an effective amount of a compound of formula (I) and an effective amount of a bronchodilator.

30 The present invention also provides a composition comprising a compound of formula (I), a bronchodilator, and a pharmaceutically acceptable carrier.

- 19 -

5 In the treatment of the conditions associated with an excess of tachykinins, a suitable dosage level is about 0.001 to 50 mg/kg per day, in particular about 0.01 to about 25 mg/kg, such as from about 0.05 to about 10 mg/kg of a compound of formula (I) per day.


10 For example, in the treatment of conditions involving the neurotransmission of pain sensations, a suitable dosage level is about 0.001 to 25 mg/kg per day, preferably about 0.005 to 10 mg/kg per day, and especially about 0.005 to 5 mg/kg per day. The compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.

15 In the treatment of emesis using an injectable formulation, a suitable dosage level is about 0.001 to 10 mg/kg per day, preferably about 0.005 to 5 mg/kg per day, and especially 0.01 to 1 mg/kg per day. The compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.

20 It will be appreciated that the amount of a compound of formula (I) required for use in any treatment will vary not only with the particular compounds or composition selected but also with the route of administration, the nature of the condition being treated, and the age and condition of the patient, and 25 will ultimately be at the discretion of the attendant physician.

30 Compounds of formula (I) wherein X represents $C(=O)CH=CH$ or $C(=O)CH=C(C_{1-6}alkyl)$ may be prepared by reaction of compounds of formula (II) with compounds of formula (III):

- 20 -




wherein R^1 , R^2 , R^3 , m and n are as defined for formula (I) and R^{30} represents H or C_{1-6} alkyl, in the presence of a base.

Suitable bases of use in the reaction include alkali metal alkoxides such as, for example, sodium methoxide.

15 The reaction is conveniently effected in a suitable organic solvent such as an alcohol, for example, methanol.

Compounds of formula (I) wherein X represents
CH=CHC(=O) or C(C₁₋₆alkyl)=CHC(=O) may be prepared by
reaction of compounds of formula (IV) with compounds of
formula (V):



30 wherein R^1 , R^2 , R^3 , m and n are as defined for formula (I) and R^{31} represents alkoxy, in the presence of a base.

Suitable bases of use in the reaction include alkali metal carbonates such as, for example, potassium carbonate.

- 21 -

The reaction is conveniently carried out in a suitable organic solvent such as, for example, acetonitrile.

Other compounds of formula (I) may be prepared 5 from compounds of formula (I) wherein X is $C(=O)CH=CH$, $C(=O)CH=C(C_1-6\text{alkyl})$, $CH=CHC(=O)$ and $C(C_1-6\text{alkyl})=CHC(=O)$ by suitable interconversion procedures.

For example, compounds of formula (I) wherein X contains a carbon-carbon double bond may be converted to 10 compounds of formula (I), wherein X contains no carbon-carbon double bond by reduction. Suitable procedures will be readily apparent to those skilled in the art and include catalytic hydrogenation, for example, using a nobel metal catalyst such as rhodium, platinum or, 15 preferably, palladium, which may be supported, for example on carbon, and reaction with an alkyl tin hydride such as tributyl tin hydride.

Compounds of formula (I) wherein R^4 and R^5 together represent $=O$ or R^6 and R^7 together represent $=O$ 20 may be converted to the corresponding alcohols wherein one of R^4 and R^5 or one of R^6 and R^7 is H and the other of R^4 and R^5 or R^6 and R^7 is hydroxy by conventional reduction methods. Suitable reducing agents include 25 hydride reducing agents such as, for example, sodium borohydride.

Compounds of formula (I) wherein at least one of R^4 , R^5 , R^6 and R^7 represents $C_1-6\text{alkoxy}$ may be prepared from the corresponding alcohol of formula (I) by 30 alkylation. Suitable procedures will be readily apparent to those skilled in the art and include reaction with an alkyl halide, such as, for example, an alkyl iodide, in the presence of a base, such as an alkali metal hydride, for example sodium hydride.

- 22 -

Compounds of formula (I) wherein R⁴ and R⁵ or R⁶ and R⁷ together form =O may be converted to compounds of formula (I) wherein one or both of R⁴ and R⁵ or R⁶ and R⁷ represent C₁-6alkyl by reaction with a Grignard reagent of formula R⁴MgHal and/or R⁵MgHal or R⁶MgHal and/or R⁷MgHal wherein Hal represents halo such as chloro, bromo or iodo.

Compounds of formula (I) wherein X represents CR⁴R⁵CH=CH or CH=CHCR⁶R⁷ may be prepared from the corresponding compounds of formula (I) wherein X represents CR⁴R⁵CH₂CHOH or CH(OH)CH₂CR⁶R⁷ by treatment with Burgess Reagent ((methoxycarbonylsulphamoyl)-triethylammonium hydroxide, inner salt).

Interconversion processes may also be used to vary the group R³. For example, compounds of formula (I), (II) or (IV) wherein R³ is other than H may be prepared from the corresponding compounds of formula (I), (II) or (IV) wherein R³ is H by conventional methods, such as reaction with a compound R³-Hal, where Hal represents halo, in the presence of a base. Suitable reagents and conditions will be readily apparent to those skilled in the art. Suitable bases include organic bases, such as tertiary amines, e.g. triethylamine, and inorganic bases, such as alkali metal carbonates, e.g. sodium carbonate. Compounds of formula (I), (II) or (IV) wherein R³ is COR⁹ may also be prepared from corresponding compounds of formula (I), (II) or (IV) wherein R³ is H by, for example, reaction with an appropriate acid anhydride. Compounds of formula (I), (II) or (IV) wherein R³ is C₁-6alkyl may be prepared from corresponding compounds of formula (I), (II) or (IV) wherein R³ is COR⁹ by reduction using, for example, borane or a borohydride such as sodium cyanoborohydride. Suitable procedures will be readily apparent to those


- 23 -

skilled in the art. Compounds of formula (I), (II) or (IV) wherein R³ is C₁₋₆alkyl substituted by CONR¹⁰R¹¹ may be prepared from corresponding compounds of formula (I), (II) or (IV) wherein R³ is C₁₋₆alkyl substituted by CO₂R¹⁰ by treatment with ammonia or an amine of formula NR¹⁰R¹¹.

Compounds of formula (II) wherein R³ is H are commercially available or may be prepared by known procedures.

Compounds of formulae (III) and (V) are commercially available or may be prepared from commercially available compounds by procedures well known in the art.

Compounds of formula (IV) may be prepared from the corresponding compounds of formula (VI)



(VI)

wherein R², R³, m and n are as previously defined, by reduction.

A suitable reducing agent for use in the reaction is diisobutyl aluminium hydride.

Compounds of formula (VI) are commercially available or may be prepared by known procedures.

Where the above-described process for the preparation of the compounds according to the invention gives rise to mixtures of stereoisomers these isomers

- 24 -

may, if desired, be separated, suitably by conventional techniques such as preparative chromatography.

The novel compounds which contain one or more chiral centres may be prepared in racemic form, or 5 individual enantiomers may be prepared either by enantiospecific synthesis or by resolution.

During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This 10 may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991. The 15 protecting groups may be removed at a convenient subsequent stage using methods known from the art.

The exemplified compounds of the invention were tested by the methods set out at pages 36 to 39 of International Patent Specification No. WO 93/01165. The 20 compounds were found to be active with IC₅₀ at the NK₁ receptor of less than 300nM.

The compounds of this invention may be formulated as specifically illustrated at pages 35 to 36 of International Patent Specification No. 93/01165.

25 The following Examples illustrate the preparation of compounds according to the invention.

EXAMPLE 14-(3',5'-Bis(trifluoromethyl)phenyl)propionyl)-4-phenylpiperidine Hydrochloride5 (a) 4-Acetyl-N-^tbutoxycarbonyl-4-phenylpiperidine

4-Acetyl-4-phenylpiperidine hydrochloride was dissolved in water, the solution was made basic by addition of potassium carbonate, and the mixture was extracted with ethyl acetate. 10 The extracts were dried (Na_2SO_4) and concentrated to give 4-acetyl-4-phenylpiperidine. To a solution of this compound (2.2g) in dichloromethane (50ml) was added di-^tbutyl dicarbonate (2.8g). After 15 minutes the solution was washed with water, dried, concentrated and the residue crystallised from petroleum ether to give the title compound, mp 91-92°C. 15

20 (b) N-^tButoxycarbonyl-4-(3',5'-bis(trifluoromethyl)cinnamoyl)-4-phenylpiperidine

The compound of part (a) (9.3g) in methanol (250ml) was heated under reflux with 3,5-bis(trifluoromethyl)benzaldehyde (12.5g) in the presence of sodium methoxide (0.5g) for 3 hours. The solvent was removed *in vacuo* and the residue partitioned between water and ethyl acetate. The ethyl acetate solution was separated, dried and concentrated to give a residue which was purified by chromatography on silica gel eluting with ethyl acetate-petroleum ether (1:9) to give the title compound. ¹H NMR (250MHz, CDCl_3) δ 1.45 (9H, s), 1.90-2.18 (2H, m), 2.40-2.50 (2H, m), 3.01-3.30 (2H, m), 3.70-4.10 (2H, m), 6.72 (1H, d, J

= 16Hz), 7.26-7.44 (5H, m), 7.66 (1H, d, J = 16Hz), 7.79 (2H, s), 7.82 (1H, s).

5 (c) 4-(3-(3',5'-Bis(trifluoromethyl)phenyl)propionyl)-4-phenylpiperidine Hydrochloride

The compound of part (b) (7.2g) in toluene (50ml) was purged with nitrogen gas and tributyltin hydride (4.8g) was added. The reaction was heated to reflux for 16 hours then cooled and 10 concentrated *in vacuo*. The product was purified by chromatography on silica eluting with ethyl acetate/petroleum ether (3:7), then dissolved in ethereal hydrogen chloride for 16 hours. The solvent was then evaporated to yield the title compound, mp 164-165°C; found: C, 56.82; H, 4.75; N, 2.95. 15 $C_{22}H_{21}F_6NO \cdot HCl$ requires C, 56.72; H, 4.76; N, 3.01.

EXAMPLE 2

20 4-(3-(3',5'-Bis(trifluoromethyl)phenyl)-1-hydroxy-3-propenyl)-4-phenylpiperidine Hydrochloride

The compound of Example 1(b) (1g) in methanol (20ml) was stirred with sodium borohydride (0.2g) for 1 hour. The solution was poured into water and extracted with ethyl acetate which 25 was then dried (Na_2SO_4) and concentrated *in vacuo*. The residue was purified by chromatography on silica gel eluting with ethyl acetate-petroleum ether (3:7) then dissolved in ethereal hydrogen chloride. The solid which crystallised from solution was filtered to give the title compound, mp 174-175°C; found: C, 30 53.98; H, 4.76; N, 2.94. $C_{22}H_{21}F_6NO \cdot HCl \cdot 1.25H_2O$ requires C, 54.10; H, 5.06; N, 2.89.

EXAMPLE 34-(3-(3',5'-Bis(trifluoromethyl)phenyl)-1-methoxy-3-propenyl)-4-phenylpiperidine Hydrochloride

5

The compound of Example 1(b) was reduced with sodium borohydride as described in Example 2. After purification on silica gel the product was treated with sodium hydride and methyl iodide in dimethylformamide for one hour. The solution was poured onto water and extracted with ethyl acetate which was then dried (Na_2SO_4) and concentrated. The residue was purified by chromatography on silica gel eluting with ethyl acetate-petroleum ether (15:85), then dissolved in ethereal hydrogen chloride. The solid which crystallised from solution was filtered and dried to give the title compound, mp 282°C; found: C, 57.06; H, 4.93; N, 2.88. $\text{C}_{23}\text{H}_{23}\text{F}_6\text{NO.HCl.0.25H}_2\text{O}$ requires C, 57.03; H, 5.10; N, 2.89.

20

EXAMPLE 44-(3-(3',5'-Bis(trifluoromethyl)phenyl)-1-hydroxypropyl)-4-phenylpiperidine Hydrochloride

25

The compound of Example 1(b) was treated with tributyltin hydride as described in Example 1(c). After purification on silica gel the product was reduced using sodium borohydride and treated with ethereal hydrogen chloride, as described in Example 2, to give the title compound, mp 90-91°C; found: C, 54.81; H, 5.04; N, 2.86. $\text{C}_{22}\text{H}_{23}\text{F}_6\text{NO.HCl.0.75H}_2\text{O}$ requires C, 54.89; H, 5.34; N, 2.91.

EXAMPLE 54-(3-(3',5'-Bis(trifluoromethyl)phenyl)-1-methoxypropyl)-4-phenylpiperidine Hydrochloride

5

The compound of Example 1(b) was treated with tributyltin hydride then sodium borohydride as described in Example 4. After purification on silica gel the product was reacted with sodium hydride and methyl iodide by the method of Example 3. The product was purified on silica gel and dissolved in ethereal hydrogen chloride for 16 hours. The solvent was removed *in vacuo* to give the title compound, mp 65-67°C; found: C, 57.58; H, 5.36; N, 2.87. $C_{23}H_{25}F_6NO \cdot HCl$ requires C, 57.32; H, 5.44; N, 2.91.

10

15

EXAMPLE 64-(3-(3',5'-Bis(trifluoromethyl)phenyl)-3-ketopropyl)-4-phenylpiperidine Hydrochloride

20

(a) Dimethyl 2-(3,5-bis(trifluoromethyl)phenyl-2-ketoethylphosphonate

25

Dimethyl methylphosphonate (50.1g) in tetrahydrofuran (500ml) was treated with butyl lithium (165ml of a 2.5M solution in hexane) at -78°C under an atmosphere of nitrogen. After 1 hour, methyl 3,5-bis(trifluoromethyl)benzoate (18.7g) in tetrahydrofuran (50ml) was added slowly and stirred for 0.5 hours. The reaction was quenched with 5N hydrochloric acid (500ml) and the tetrahydrofuran evaporated *in vacuo*. The resulting mixture was extracted with ethyl acetate which was

then dried and concentrated under reduced pressure. The residue was distilled under vacuum at 1mm Hg to give the title compound, bp 160-162°C.

5 (b) N-^tButoxycarbonyl-4-phenyl-4-cyano piperidine

10 Di-^tbutyldicarbonate (20g) was added to a stirred solution of 4-phenyl-4-cyano piperidine hydrochloride (20g) and Et₃N (9.5g) in dry dichloromethane (100ml). The resulting solution was stirred for 18 hours at room temperature. The reaction mixture was washed with water (100ml) and the organic layer separated and dried over MgSO₄. Filtration and removal of solvent under reduced pressure afforded a white solid. Recrystallisation from hexane gave the title compound as white needles, mp = 64°C. ¹H NMR (360MHz, CDCl₃) δ 1.46 (9H, s), 1.90 (2H, m), 2.04 (2H, m), 3.20 (2H, m), 4.26 (2H, m), 7.26-7.49 (5H, m); MS (Cl⁺) 287 (M + H⁺).

15 (c) N-^tButoxycarbonyl-4-phenylpiperidine-4-carboxaldehyde

20 A solution of N-^tButoxycarbonyl-4-phenyl-4-cyano piperidine (5.0g) in dry toluene (100ml) at -78°C was treated with a solution of DIBALH (27.7ml x 1.0mol) in toluene. The reaction was maintained at -78°C for two hours, at which time it was quenched by slow addition of a saturated solution of NH₄Cl (20ml), and allowed to warm to room temperature. The reaction mixture was poured into water (100ml) and extracted into ethyl acetate. The organic layers were separated, dried over MgSO₄, filtered and solvent removed to give a yellow oil. Chromatography on silica gel (20% EtOAc in hexane) afforded

the product as a clear oil (2.1g). ^1H NMR (360MHz, CDCl_3) δ 1.45 (9H, s), 1.95 (2H, m), 2.07 (2H, m), 3.12 (2H, m), 3.85 (2H, m), 7.26-7.40 (5H, m), 9.40 (1H, s); MS (CI $^+$) 290 (M + H $^+$).

5 (d) 4-(3-(3',5'-Bis(trifluoromethyl)phenyl)-3-keto-2-propenyl)-4-phenyl-N- t -butoxycarbonylpiperidine

10 The compounds of Examples 6(a) (4.6g) and 6(c) (5.8g) were stirred in dimethylformamide (100ml) in the presence of sodium hydride (0.8g of a 60% dispersion in oil) for 1 hour. i Propyl alcohol was added then the solvents were removed *in vacuo*. The residue was purified on silica gel eluting with ethyl acetate-petroleum ether (1:9) to give the title compound. ^1H NMR (360MHz, CDCl_3) δ 1.46 (9H, s), 1.86-2.10 (2H, m), 2.30-2.46 (2H, m), 3.04-3.20 (2H, m), 3.84-3.98 (2H, m), 7.21-7.48 (5H, m), 7.99 (1H, s), 8.10 (2H, s).

20 (e) 4-(3-(3',5'-Bis(trifluoromethyl)phenyl)-3-ketopropyl)-4-phenyl-N- t -butoxycarbonylpiperidine

25 The compound of Example 6(c) (1.4g) was shaken in ethanol (25ml) under an atmosphere of hydrogen over 10% Pd-C (1g) at 50 psi for 16 hours. The mixture was filtered and evaporated to give the title compound. ^1H NMR (360MHz, CDCl_3) δ 1.45 (9H, s), 2.04-2.14 (2H, m), 2.25-2.35 (2H, m), 3.42-3.49 (2H, m), 3.55-3.62 (2H, m), 6.61 (1H, d, J = 16Hz), 7.15 (1H, d, J = 16Hz), 7.26-7.46 (5H, m), 8.03 (1H, s), 8.22 (2H, s).

30 (f) 4-(3-(3',5'-Bis(trifluoromethyl)phenyl)-3-ketopropyl)-4-phenylpiperidine Hydrochloride

The compound of Example 6(d) was treated with ethereal hydrogen chloride for 16 hours then concentrated *in vacuo* to give the title compound as a white solid, mp 54-55°C; found: C, 55.48; H, 4.74; N, 2.78. $C_{22}H_{21}F_6NO \cdot HCl \cdot 0.5H_2O$ requires C, 55.64; H, 4.88; N, 2.95.

5

EXAMPLE 7

10 4-(3-(3',5'-Bis(trifluoromethyl)phenyl)-3-hydroxypropyl)-4-phenylpiperidine Hydrochloride

(a) 4-(3-(3',5'-Bis(trifluoromethyl)phenyl)-3-hydroxypropyl)-N-^tbutoxycarbonyl-4-phenylpiperidine

15

The compound of Example 6(e) (1.5g) in methanol (20ml) was treated with sodium borohydride (0.3g) for 1 hour. The reaction mixture was poured onto water and extracted with ethyl acetate which was then dried (Na_2SO_4) and concentrated. The residue was purified by chromatography on silica gel eluting with ethyl acetate-petroleum ether (1:4) to give the title compound. 1H NMR (360MHz, $CDCl_3$) δ 1.43 (9H, s), 1.47-1.73 (2H, m), 2.04-2.17 (2H, m), 3.02-3.14 (2H, m), 3.58-3.66 (2H, m), 4.56-4.58 (1H, m), 7.19-7.34 (5H, m), 7.61 (2H, s), 7.74 (1H, s).

20

25

(b) 4-(3-(3',5'-Bis(trifluoromethyl)phenyl)-3-hydroxypropyl)-4-phenylpiperidine Hydrochloride

30

The compound of part (a) was dissolved in ethereal hydrogen chloride for 16 hours. The solvent was evaporated *in vacuo* to give the title compound, mp 95-96°C.

EXAMPLE 8

4-(3-(3',5'-Bis(trifluoromethyl)phenyl)-3-methoxypropyl)-4-phenylpiperidine Hydrochloride

5

The compound of Example 7(a) (0.5g) in dimethylformamide (20ml) was stirred with methyl iodide (0.29g) and sodium hydride (0.06g of a 60% suspension in oil) for 16 hours. The reaction mixture was diluted with ethyl acetate, washed with water, dried (Na_2SO_4) and concentrated. The residue was purified by chromatography on silica gel then dissolved in ethereal hydrogen chloride for 16 hours. The solvent was removed under reduced pressure to give the title compound as a

10

15

R- and S-4-(3-(3',5'-Bis(trifluoromethyl)phenyl)-3-hydroxypropyl)-4-phenylpiperidine Hydrochloride

20

25

30

The compound of Example 7(a) (100mg) was dissolved in dichloromethane (10ml) and stirred for 1.5 hours with triethylamine (0.03ml), 4-(dimethylamino)pyridine (5mg) and α -methoxyl- α -(trifluoromethyl)phenylacetyl chloride (0.04ml). The solvent was removed under reduced pressure and the residue partitioned between ethyl acetate and water. The ethyl acetate solution was concentrated and the residue purified by chromatography on silica gel eluting with ethyl acetate-petroleum ether (7:93) to give two products, diastereomer A and diastereomer B. These two diastereomers were individually heated under reflux with sodium hydroxide in methanol for 1

hour. In each case the solvent was removed *in vacuo* and the residue purified by chromatography on silica gel eluting with ethyl acetate-petroleum ether (1:4) to give R- and S-4-(3-(3',5'-bis(trifluoromethyl)phenyl)-3-hydroxypropyl)-N-^tbutoxycarbonyl-4-phenylpiperidine. These two enantiomers were individually treated with ethereal hydrogen chloride as described in Example 7(b) to give the title compounds. Enantiomer A, mp 81-82°C, α_D (c=1.03, MeOH) = +9.32°; Enantiomer B, mp 83-84°C, α_D (c=0.96, MeOH) = -8.85°.

10

EXAMPLE 104-(3-(3',5'-Bis(trifluoromethyl)phenyl)-3-hydroxy-3-methylpropyl)-4-phenylpiperidine Hydrochloride

15

The compound of Example 6(c) (0.41g) in diethyl ether (10ml) was treated with methylmagnesium bromide (0.8ml of a 3M solution in tetrahydrofuran) for 5 minutes after which time water was added and extracted with diethyl ether. The ethereal extracts were dried (Na_2SO_4) and concentrated to give a residue which was purified by chromatography on silica gel eluting with ethyl acetate-petroleum ether (1:3). The resulting oil was treated with ethereal hydrogen chloride for 4 hours then concentrated to give the title compound as a white solid, mp 213-215°C; found: C, 56.26; H, 5.42; N, 2.93. $\text{C}_{23}\text{H}_{25}\text{F}_6\text{NO.HCl}$. 0.5H₂O requires C, 56.27; H, 5.54; N, 2.85.

30

4-(3-(3',5'-Bis(trifluoromethyl)phenyl)-3-hydroxy-3-ethylpropyl)-4-phenylpiperidine HydrochlorideEXAMPLE 11

Prepared by the method of Example 10 using ethylmagnesium bromide. Mp 105°C; found: C, 57.13; H, 5.83; N, 2.76. $C_{24}H_{27}F_6NO \cdot HCl \cdot 0.5H_2O$ requires C, 57.09; H, 5.79; N, 2.77.

5

EXAMPLE 12

10 4-(3-(3',5'-Bis(trifluoromethyl)phenyl)propyl)-4-phenylpiperidine Hydrochloride

The compound of Example 7(a) (0.7g) in dichloromethane (50ml) with 4-(dimethylamino)pyridine (0.32g) was cooled to 0°C. Phenyl chlorothiocarbamate (0.43g) was added and the solution allowed to warm to 20°C and stirred for 16 hours. The mixture was diluted with ethyl acetate and washed successively with a solution of citric acid in water, then water, sodium bicarbonate solution, and water. The solution was dried (Na_2SO_4), concentrated and the residue purified by chromatography on 15 silica gel eluting with ethyl acetate-petroleum ether (1:9). The resulting product was dissolved in toluene (25ml) which was purged with nitrogen gas. Alpha, alpha'-azoisobutyronitrile (0.49g) and tributyltin hydride (0.58g) were added and the solution was heated under reflux for 5 hours then cooled and 20 concentrated under reduced pressure. The residue was purified by chromatography on silica gel eluting with ethyl acetate-petroleum ether (1:9) then treated with ethereal hydrogen chloride for 16 hours. The solvent was removed *in vacuo* and the residue crystallised from ethyl acetate to give the title 25 compound. 1H NMR (360MHz, D_6 -DMSO) δ 1.22-1.32 (2H, m), 1.54-1.64 (2H, m), 1.83-1.94 (2H, m), 2.26-2.34 (2H, m), 2.62 (2H, 30

t, J = 7.5Hz), 2.72 (2H, t, J = 10Hz), 3.08-3.18 (2H, m), 7.21-7.37 (5H, m), 7.76 (2H, s), 7.86 (1H, s), 8.74 (1H, s); MS (CI⁺) 416 (M+H)⁺.

5

EXAMPLE 135-[4-(3-(3',5'-Bis(trifluoromethyl)phenyl)propyl)-4-phenylpiperidin-1-ylmethyl]-2,4-dihydro-1,2,4-triazol-3-one

10 N-t-Butoxychloromethyl imidrazone (104.4mg) was added to a stirred suspension of the compound of Example 12 (310mg) and K₂CO₃ (1.0g) in dry dimethylformamide (15ml). The resulting mixture was stirred at room temperature for 18 hours. The reaction mixture was then diluted with water (50ml) and extracted into ethyl acetate (50ml). The organic extract was washed with water (4 x 20ml), brine (50ml) and dried over MgSO₄. Filtration and removal of solvent under reduced pressure afforded a yellow crystalline solid (290mg) which was re-dissolved in dry toluene (20ml) and warmed to reflux in the presence of a catalytic amount of potassium t-butoxide. After 4 hours the reaction was cooled to room temperature and the solvent removed under reduced pressure. Recrystallisation from diethyl ether-hexane afforded the title compound as a white powder, mp 104-105°C.

25

EXAMPLE 145-[4-(3-(3',5'-Bis(trifluoromethyl)phenyl)-3-hydroxypropyl)-4-phenylpiperidin-1-ylmethyl]-2,4-dihydro-1,2,4-triazol-3-one


30

Prepared from the compound of Example 7 using the method of Example 7 using the method of Example 14. Mp 110°C; found: C, 55.30; H, 5.05; N, 10.09. $C_{25}H_{26}F_6N_4O_2 \cdot 0.75H_2O$ requires C, 55.40; H, 5.11; N, 10.33.

- 37 -

CLAIMS

1. A compound of formula (I), or a
 5 pharmaceutically acceptable salt or prodrug thereof:



15 wherein

X represents a propylene or propenylene chain
 optionally substituted by one or more of R⁴, R⁵, R⁶ and
 R⁷;

m is 2, 3 or 4;

20 n is 0, 1 or 2 when m is 2 or 3, and n is 0 or
 1 when m is 4;

25 R¹ represents phenyl optionally substituted by
 1, 2 or 3 groups selected from C₁-6alkyl, C₂-6alkenyl,
 C₂-6alkynyl, C₃-6cycloalkyl, C₃-5cycloalkylmethyl, halo,
 cyano, nitro, trifluoromethyl, trimethylsilyl, -OR^a,
 -SR^a, -SOR^a, -SO₂R^a, -NR^aR^b, -NR^aCOR^b, -NR^aCO₂R^b, -CO₂R^a
 or -CONR^aR^b, where R^a and R^b each independently represent
 H, C₁-6alkyl, phenyl or trifluoromethyl;

30 R² represents phenyl optionally substituted by
 1, 2 or 3 groups selected from C₁-6alkyl, C₂-6alkenyl,
 C₂-6alkynyl, C₃-6cycloalkyl, C₃-5cycloalkylmethyl, halo,
 cyano, nitro, trifluoromethyl, trimethylsilyl, -OR^a,
 -SR^a, -SOR^a, -SO₂R^a, -NR^aR^b, -NR^aCOR^b, -NR^aCO₂R^b, -CO₂R^a
 or -CONR^aR^b, where R^a and R^b are as previously defined;

heteroaryl selected from indazolyl, thienyl, furyl, pyridyl, thiazolyl, tetrazolyl and quinolyl; benzhydryl; or benzyl; wherein each heteroaryl and each phenyl moiety of benzyl and benzhydryl may be substituted by C₁₋₆alkyl, C₁₋₆alkoxy, halo or trifluoromethyl;

5 R³ represents H, COR⁹, COCONR¹⁰R¹¹, COCO₂R¹⁰, SO₂R¹⁵, CONR¹⁰SO₂R¹⁵, C₁₋₆alkyl optionally substituted by a group selected from (CO₂R¹⁰, CONR¹⁰R¹¹, hydroxy, cyano, COR⁹, NR¹⁰R¹¹, C(NO₂)NR¹⁰R¹¹, CONHphenyl(C₁₋₄alkyl), COCO₂R¹⁰, COCONR¹⁰R¹¹, SO₂R¹⁵, CONR¹⁰SO₂R¹⁵ and phenyl optionally substituted by one or more substituents selected from C₁₋₆alkyl, C₁₋₆alkoxy, halo and trifluoromethyl), Y-R⁸ or CO-Z-(CH₂)_q-R¹²;

10 R⁴ and R⁵ each independently represents H, C₁₋₆alkyl, C₃₋₆cycloalkyl, C₃₋₅cycloalkylmethyl, hydroxy or C₁₋₆alkoxy, or R⁴ and R⁵ together form a group =O; R⁶ and R⁷ each independently represents H, C₁₋₆alkyl, C₃₋₆cycloalkyl, C₃₋₅cycloalkylmethyl, hydroxy or C₁₋₆alkoxy or R⁶ and R⁷ together form a group =O;

15 20 R⁸ represents an optionally substituted aromatic heterocycle;

R⁹ represents H, C₁₋₆alkyl, C₃₋₆cycloalkyl, C₃₋₅cycloalkylmethyl, or phenyl;

25 R¹⁰ and R¹¹ each independently represent H, C₁₋₆alkyl, C₃₋₆cycloalkyl or C₃₋₅cycloalkylmethyl; R¹² represents NR¹³R¹⁴ or an optionally substituted aromatic or non-aromatic azacyclic or azabicyclic group;

30 R¹³ and R¹⁴ each independently represent H, C₁₋₆alkyl, C₃₋₆cycloalkyl, C₃₋₅cycloalkylmethyl, phenyl optionally substituted by one or more of C₁₋₆alkyl, C₁₋₆alkoxy, halo or trifluoromethyl or phenylC₁₋₄alkyl optionally substituted in the phenyl ring by one or more of C₁₋₆alkyl, C₁₋₆alkoxy, halo or trifluoromethyl;


- 39 -

R^{15} represents C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{3-5} cycloalkylmethyl, trifluoromethyl or phenyl optionally substituted by one or more substituents selected from C_{1-6} alkyl, C_{1-6} alkoxy, halo and trifluoromethyl;

5 Y represents a hydrocarbon chain of 1, 2, 3 or 4 carbon atoms which may optionally be substituted by oxo;

10 Z represents CH_2 , O, S or NR^{10} ; and q represents 0, 1, 2, 3, 4, 5 or 6.

2. A compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof:



(I)

wherein

25 X represents a group $CR^4R^5CH_2CR^6R^7$, $CR^4=CHCR^6R^7$ or $CR^4R^5CH=CR^6$;

m is 2, 3 or 4;

n is 0, 1 or 2 when m is 2 or 3, and n is 0 or 1 when m is 4;

30 R^1 represents phenyl optionally substituted by 1, 2 or 3 groups selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl, C_{3-5} cycloalkylmethyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, $-OR^a$,

- 40 -

$-\text{SR}^a$, $-\text{SOR}^a$, $-\text{SO}_2\text{R}^a$, $-\text{NR}^a\text{R}^b$, $-\text{NR}^a\text{COR}^b$, $-\text{NR}^a\text{CO}_2\text{R}^b$, $-\text{CO}_2\text{R}^a$ or $-\text{CONR}^a\text{R}^b$, where R^a and R^b each independently represent H, $\text{C}_1\text{-6alkyl}$, phenyl or trifluoromethyl;

5 R^2 represents phenyl optionally substituted by 1, 2 or 3 groups selected from $\text{C}_1\text{-6alkyl}$, $\text{C}_2\text{-6alkenyl}$, $\text{C}_2\text{-6alkynyl}$, $\text{C}_3\text{-6cycloalkyl}$, $\text{C}_3\text{-5cycloalkylmethyl}$, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, $-\text{OR}^a$, $-\text{SR}^a$, $-\text{SOR}^a$, $-\text{SO}_2\text{R}^a$, $-\text{NR}^a\text{R}^b$, $-\text{NR}^a\text{COR}^b$, $-\text{NR}^a\text{CO}_2\text{R}^b$, $-\text{CO}_2\text{R}^a$ or $-\text{CONR}^a\text{R}^b$, where R^a and R^b are as previously defined;

10 heteroaryl selected from indazolyl, thienyl, furyl, pyridyl, thiazolyl, tetrazolyl and quinolyl; benzhydryl; or benzyl; wherein each heteroaryl and each phenyl moiety of benzyl and benzhydryl may be substituted by $\text{C}_1\text{-6alkyl}$, $\text{C}_1\text{-6alkoxy}$, halo or trifluoromethyl;

15 R^3 represents H, COR^9 , CO_2R^{10} , $\text{COCONR}^{10}\text{R}^{11}$, $\text{COCO}_2\text{R}^{10}$, SO_2R^{15} , $\text{CONR}^{10}\text{SO}_2\text{R}^{15}$, $\text{C}_1\text{-6alkyl}$ optionally substituted by a group selected from $(\text{CO}_2\text{R}^{10}$, $\text{CONR}^{10}\text{R}^{11}$, hydroxy, cyano, COR^9 , $\text{NR}^{10}\text{R}^{11}$, $\text{C}(\text{NOH})\text{NR}^{10}\text{R}^{11}$, $\text{CONHphenyl}(\text{C}_1\text{-4alkyl})$, $\text{COCO}_2\text{R}^{10}$, $\text{COCONR}^{10}\text{R}^{11}$, SO_2R^{15} , 20 $\text{CONR}^{10}\text{SO}_2\text{R}^{15}$ and phenyl optionally substituted by one or more substituents selected from $\text{C}_1\text{-6alkyl}$, $\text{C}_1\text{-6alkoxy}$, halo and trifluoromethyl), Y-R^8 or $\text{CO-Z-(CH}_2\text{)}_q\text{-R}^{12}$;

25 R^4 and R^5 each independently represents H, $\text{C}_1\text{-6alkyl}$, $\text{C}_3\text{-6cycloalkyl}$, $\text{C}_3\text{-5cycloalkylmethyl}$, hydroxy or $\text{C}_1\text{-6alkoxy}$, or R^4 and R^5 together form a group $=\text{O}$;

30 R^6 and R^7 each independently represents H, $\text{C}_1\text{-6alkyl}$, $\text{C}_3\text{-6cycloalkyl}$, $\text{C}_3\text{-5cycloalkylmethyl}$, hydroxy or $\text{C}_1\text{-6alkoxy}$ or R^6 and R^7 together form a group $=\text{O}$;

35 R^8 represents an optionally substituted aromatic heterocycle;

40 R^9 represents H, $\text{C}_1\text{-6alkyl}$, $\text{C}_3\text{-6cycloalkyl}$, $\text{C}_3\text{-5cycloalkylmethyl}$, or phenyl;

45 R^{10} and R^{11} each independently represent H, $\text{C}_1\text{-6alkyl}$, $\text{C}_3\text{-6cycloalkyl}$ or $\text{C}_3\text{-5cycloalkylmethyl}$;

- 41 -

R^{12} represents $NR^{13}R^{14}$ or an optionally substituted aromatic or non-aromatic azacyclic or azabicyclic group;

5 R^{13} and R^{14} each independently represent H, C_1 - 6 alkyl, C_3 - 6 cycloalkyl, C_3 - 5 cycloalkylmethyl, phenyl optionally substituted by one or more of C_1 - 6 alkyl, C_1 - 6 alkoxy, halo or trifluoromethyl or phenyl C_1 - 4 alkyl optionally substituted in the phenyl ring by one or more of C_1 - 6 alkyl, C_1 - 6 alkoxy, halo or trifluoromethyl;


10 R^{15} represents C_1 - 6 alkyl, C_3 - 6 cycloalkyl, C_3 - 5 cycloalkylmethyl, trifluoromethyl or phenyl optionally substituted by one or more substituents selected from C_1 - 6 alkyl, C_1 - 6 alkoxy, halo and trifluoromethyl;

15 V represents a hydrocarbon chain of 1, 2, 3 or 4 carbon atoms which may optionally be substituted by oxo;

Z represents CH_2 , O, S or NR^{10} ; and q represents 0, 1, 2, 3, 4, 5 or 6.

20

3. A compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof:



(I)

wherein

X represents a group $CR^4R^5CH_2CR^6R^7$, $CR^4=CHCR^6R^7$ or $CR^4R^5CH=CR^6$;

- 42 -

m is 2, 3 or 4;

n is 0, 1 or 2 when m is 2 or 3, and n is 0 or 1 when m is 4;

5 R¹ represents phenyl optionally substituted by 1, 2 or 3 groups selected from C₁-6alkyl, C₂-6alkenyl, C₂-6alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, -OR^a, -SR^a, -SOR^a, -SO₂R^a, -NR^aR^b, -NR^aCOR^b, -NR^aCO₂R^b, -CO₂R^a or -CONR^aR^b, where R^a and R^b each independently represent H, C₁-6alkyl, phenyl or 10 trifluoromethyl;

15 R² represents phenyl optionally substituted by 1, 2 or 3 groups selected from C₁-6alkyl, C₂-6alkenyl, C₂-6alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, -OR^a, -SR^a, -SOR^a, -SO₂R^a, -NR^aR^b, -NR^aCOR^b, -NR^aCO₂R^b, -CO₂R^a or -CONR^aR^b, where R^a and R^b are as previously defined; heteroaryl selected from indazolyl, thienyl, furyl, pyridyl, thiazolyl, tetrazolyl and quinolyl; benzhydryl; or benzyl; wherein each heteroaryl and each phenyl moiety of benzyl and 20 benzhydryl may be substituted by C₁-6alkyl, C₁-6alkoxy, halo or trifluoromethyl;

25 R³ represents H, COR⁹, CO₂R¹⁰, COCONR¹⁰R¹¹, COCO₂R¹⁰, SO₂R¹⁵, CONR¹⁰SO₂R¹⁵, C₁-6alkyl optionally substituted by a group selected from (CO₂R¹⁰, CONR¹⁰R¹¹, hydroxy, cyano, COR⁹, NR¹⁰R¹¹, C(NOH)NR¹⁰R¹¹, CONHphenyl(C₁-4alkyl), COCO₂R¹⁰, COCONR¹⁰R¹¹, SO₂R¹⁵, CONR¹⁰SO₂R¹⁵ and phenyl optionally substituted by one or more substituents selected from C₁-6alkyl, C₁-6alkoxy, halo and trifluoromethyl), Y-R⁸ or CO-Z-(CH₂)_q-R¹²;

30 R⁴ and R⁵ each independently represents H, C₁-6alkyl, hydroxy or C₁-6alkoxy, or R⁴ and R⁵ together form a group =O;

- 43 -

R^6 and R^7 each independently represents H, C_{1-6} alkyl, hydroxy or C_{1-6} alkoxy or R^6 and R^7 together form a group =O;

5 R^8 represents an optionally substituted aromatic heterocycle;

R^9 represents H, C_{1-6} alkyl or phenyl;

R^{10} and R^{11} each independently represent H or C_{1-6} alkyl;

10 R^{12} represents $NR^{13}R^{14}$ or an optionally substituted aromatic or non-aromatic azacyclic or azabicyclic group;

15 R^{13} and R^{14} each independently represent H, C_{1-6} alkyl, phenyl optionally substituted by one or more of C_{1-6} alkyl, C_{1-6} alkoxy, halo or trifluoromethyl or phenyl C_{1-4} alkyl optionally substituted in the phenyl ring by one or more of C_{1-6} alkyl, C_{1-6} alkoxy, halo or trifluoromethyl;


20 R^{15} represents C_{1-6} alkyl, trifluoromethyl or phenyl optionally substituted by one or more substituents selected from C_{1-6} alkyl, C_{1-6} alkoxy, halo and trifluoromethyl;

 Y represents a hydrocarbon chain of 1, 2, 3 or 4 carbon atoms which may optionally be substituted by oxo;

25 Z represents CH_2 , O, S or NR^{10} ; and
 q represents 0, 1, 2, 3, 4, 5 or 6.

30 4. A compound as claimed in Claim 1 of formula (Ia), or a pharmaceutically acceptable salt or prodrug thereof:

- 44 -



(10)

10 wherein

R^3 and X are as claimed in Claim 1;

R^{20} and R^{21} independently represent H,

C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl,

C_{3-5} cycloalkylmethyl, halo, cyano, nitro,


15 trifluoromethyl, trimethylsilyl, OR^a , SR^a , SOR^a , SO_2R^a , NR^aR^b , NR^aCOR^b , $NR^aCO_2R^b$, CO_2R^a or $CONR^aR^b$, where R^a and R^b are as previously defined; and
 R^{22} represents H or halo.

20 5. A compound as claimed in any one of Claims 1 to 3 wherein m is 2 and n is 2.

25 6. A compound as claimed in any one of Claims 1 to 5 wherein R^4 , R^5 , R^6 and R^7 each independently represent H, methyl, hydroxy or methoxy or R^4 and R^5 , or R^6 and R^7 , together represent =O.

30 7. A compound as claimed in any one of Claims 1 to 6 wherein X represents a group selected from:

- 45 -



10

8. A compound as claimed in Claim 7 wherein X represents $\text{CH}_2\text{CH}_2\text{CH}(\text{OH})$.

9. A compound as claimed in any one of Claims 15 1 to 8 wherein R^1 represents phenyl substituted by 1, 2 or 3 groups selected from nitro, trifluoromethyl, trimethylsilyl, bromo, chloro, fluoro, iodo, cyano, methyl, ethyl, cyclopropyl, t-butyl, vinyl, methoxy, phenoxy, amino and carbonylmethoxy.

20

10. A compound as claimed in Claim 9 wherein R^1 represents 3,5-disubstituted phenyl wherein the substituents are selected from $\text{C}_1\text{-6alkyl}$, halo and trifluoromethyl.

25

11. A compound as claimed in Claim 10 wherein R^1 represents 3,5-bis(trifluoromethyl)phenyl.

30

12. A compound as claimed in any one of Claims 1 to 11 wherein R^2 represents unsubstituted or substituted phenyl.

13. A compound as claimed in any one of Claims 1 to 12 wherein R^3 is H.

14. A compound as claimed in any one of Claims 1 to 12 wherein R^3 is $Y-R^8$ wherein Y is as defined in Claim 1 and R^8 is selected from thienyl, furyl, pyrrolyl, 5 pyridyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, oxazolyl, oxadiazolyl, thiadiazolyl, isoxazolyl, quinolyl, isothiazolyl, imidazolyl, benzimidazolyl, benzoxazolyl, benzothiophenyl, benzofuranyl and indolyl, any of which 10 may be substituted by one or more of C_1 - 6 alkyl, C_3 - 6 cycloalkyl, C_3 - 5 cycloalkylmethyl, C_1 - 6 alkoxy, phenyl, oxo, thioxo, halo, trifluoromethyl, NR^aR^b , NR^aCOR^b , $CONR^aR^b$, CO_2R^a , SR^a , SO_2R^a and CH_2OR^a , where R^a and R^b are as defined in Claim 1.

15

15. A compound as claimed in any one of Claims 1 to 12 or 14 wherein Y represents a hydrocarbon chain of 1 or 2 carbon atoms optionally substituted by oxo.

20

16. A compound selected from
4-(3-(3',5'-bis(trifluoromethyl)phenyl)propionyl)-4-phenylpiperidine;
4-(3-(3',5'-bis(trifluoromethyl)phenyl)-1-hydroxy-3-propenyl)-4-phenylpiperidine;
25 4-(3-(3',5'-bis(trifluoromethyl)phenyl)-1-methoxy-3-propenyl)-4-phenylpiperidine;
4-(3-(3',5'-bis(trifluoromethyl)phenyl)-1-methoxypropyl)-4-phenylpiperidine;
4-(3-(3',5'-bis(trifluoromethyl)phenyl)-1-hydroxypropyl)-30 4-phenylpiperidine;
4-(3-(3',5'-bis(trifluoromethyl)phenyl)-3-ketopropyl)-4-phenylpiperidine;
4-(3-(3',5'-bis(trifluoromethyl)phenyl)-3-hydroxypropyl)-4-phenylpiperidine;

- 47 -

4-(3-(3',5'-bis(trifluoromethyl)phenyl)-3-methoxypropyl)-4-phenylpiperidine;

(R)-4-(3-(3',5'-bis(trifluoromethyl)phenyl)-3-hydroxypropyl)-4-phenylpiperidine;

5 (S)-4-(3-(3',5'-bis(trifluoromethyl)phenyl)-3-hydroxypropyl)-4-phenylpiperidine;

4-(3-(3',5'-bis(trifluoromethyl)phenyl)-3-hydroxy-3-methylpropyl)-4-phenylpiperidine;

4-(3-(3',5'-bis(trifluoromethyl)phenyl)-3-hydroxy-3-ethylpropyl)-4-phenylpiperidine;

10 4-(3-(3',5'-bis(trifluoromethyl)phenyl)propyl)-4-phenylpiperidine;

4-[4-(3-(3',5'-bis(trifluoromethyl)phenyl)propyl)-4-phenylpiperidin-1-ylmethyl]-2,4-dihydro-1,2,4-triazol-3-one;

15 5-[4-(3-(3',5'-bis(trifluoromethyl)phenyl)-3-hydroxypropyl)-4-phenylpiperidin-1-ylmethyl]-2,4-dihydro-1,2,4-triazol-3-one;

or a pharmaceutically acceptable salt or prodrug thereof.

20

17. A pharmaceutical composition comprising a compound as claimed in any one of Claims 1 to 16 or a pharmaceutically acceptable salt or prodrug thereof in association with a pharmaceutically acceptable carrier.

25

18. A compound of formula (I) as claimed in any one of Claims 1 to 16 or a pharmaceutically acceptable salt or prodrug thereof for use in therapy.

30

19. The use of a compound of formula (I) as claimed in any one of Claims 1 to 16 or a pharmaceutically acceptable salt or prodrug thereof in the manufacture of a medicament for the treatment of


- 48 -

physiological disorders associated with an excess of tachykinins, especially substance P.

5 20. A method for the treatment or prevention
of physiological disorders associated with an excess of
tachykinins, especially substance P, which method
comprises administration to a patient in need thereof of
a tachykinin reducing amount of a compound as claimed in
Claim 1, or a pharmaceutically acceptable salt of prodrug
10 thereof, or a composition comprising a compound as
claimed in Claim 1, or a pharmaceutically acceptable salt
or prodrug thereof, in association with a
pharmaceutically acceptable carrier.

15 21. A process for the preparation of a compound as claimed in any one of Claims 1 to 16 or a pharmaceutically acceptable salt or prodrug thereof which comprises:


(A) reacting a compound of formula (II) with a compound of formula (III)



30 wherein R¹, R², R³, m and n are as defined in Claim 1 and
R³⁰ represents H or C₁₋₆alkyl, in the presence of a base;
or

(B) reacting a compound of formula (IV) with a compound of formula (V)

- 49 -



10 wherein R^1 , R^2 , R^3 , m and n are as defined in Claim 1 and
 R^{31} represents C_{1-6} alkoxy, in the presence of a base;
in each case followed, if desired, by
interconversion into another compound of formula (I) or
(Ia); and/or
15 followed, if necessary, by deprotection.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 94/01576

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D211/22 C07D211/32 C07D401/12 A61K31/445

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	WO,A,94 13639 (MERCK SHARP & DOHME) 23 June 1994 see the whole document ---	1-21
P,A	WO,A,94 10165 (MERCK SHARP DOHME) 11 May 1994 see the whole document ---	1-21
A	EP,A,0 528 495 (MERCK SHARP DOHME) 24 February 1993 cited in the application see the whole document -----	1-21

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

2

Date of the actual completion of the international search

Date of mailing of the international search report

2 December 1994

- 8. 12. 94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Kissler, B

INTERNATIONAL SEARCH REPORT

I: International application No.

PCT/GB94/01576

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 20 is directed to a method of treatment of (diagnostic method practised on) the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 94/01576

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9413639	23-06-94	AU-B-	5657394	04-07-94
WO-A-9410165	11-05-94	AU-B-	5342994	24-05-94
EP-A-0528495	24-02-93	AU-A- CA-A- EP-A- WO-A-	2413892 2112397 0600952 9304040	16-03-93 04-03-93 15-06-94 04-03-93